Dyne Therapeutics, Inc. (DYN)

$7.03

+0.33 (+4.93%)
Rating:
Recommendation:
-
Symbol DYN
Price $7.03
Beta 1.604
Volume Avg. 0.16M
Market Cap 363.124M
Shares () -
52 Week Range 4.3-21.696
1y Target Est -
DCF Unlevered DYN DCF ->
DCF Levered DYN LDCF ->
ROE -40.70% Strong Sell
ROA -41.24% Strong Sell
Operating Margin -
Debt / Equity 15.25% Neutral
P/E -
P/B 1.08 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest DYN news


None
Healthcare
Biotechnology
NASDAQ Global Select

Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was incorporated in 2017 and is headquartered in Waltham, Massachusetts..